From economics to health outcomes: Delving into the significance of reduced insulin prices
The recent substantial price reductions in insulin therapy by major manufacturers prompt an examination of their impact on South Africa (SA)’s healthcare. While Eli Lilly, Novo Nordisk, and Sanofi cut prices on long-acting basal insulin, among others, significantly, these insulins are not on SA...
Saved in:
Main Authors: | M Leuschner, M Strydom, V Steenkamp |
---|---|
Format: | Article |
Language: | English |
Published: |
South African Medical Association
2024-08-01
|
Series: | South African Medical Journal |
Subjects: | |
Online Access: | https://samajournals.co.za/index.php/samj/article/view/2014 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sick Day Management for Adults with Diabetes Who Take Insulin
by: Nancy Gal, et al.
Published: (2017-08-01) -
Autophagy-lysosome pathway in insulin & glucagon homeostasis
by: Yi Wu, et al.
Published: (2025-02-01) -
Evaluating the Effect on Total Daily Insulin Dose in Adult Patients with Type 1 Diabetes Managed with Metformin and/or GLP-1 or GLP-1/GIP Receptor Agonists
by: Mayeesha Ahmed, et al.
Published: (2025-02-01) -
Muscle quality index is correlated with insulin resistance and type 2 diabetes mellitus: a cross-sectional population-based study
by: Mengye Zhang, et al.
Published: (2025-02-01) -
The Effect of Whey Protein Consumption on Postprandial Glucose, Insulin and Incretin Responses in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Acute-Term Controlled Clinical Trials
by: Zahra Salimi, et al.
Published: (2025-02-01)